Oral GLP‑1s hit distribution

A new front has opened in obesity drugs: two prescription pills now have United States approval, and Eli Lilly’s Foundayo is already shipping. (fda.gov) (lilly.com) The Food and Drug Administration approved Wegovy tablets under Novo Nordisk’s new drug application received on February 28, 2025, for long-term weight reduction in adults with obesity or overweight plus a related condition. The same labeling also covers cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight. (fda.gov 1) (fda.gov 2) Eli Lilly said Foundayo, the brand name for orforglipron, won Food and Drug Administration approval on April 1, 2026 and became available in the United States in early April through LillyDirect, retail pharmacies and telehealth providers. Lilly markets it for adults with obesity or adults with overweight and weight-related medical problems, alongside diet and exercise. (lilly.com 1) (lilly.com 2) These drugs mimic glucagon-like peptide-1, a gut hormone that helps control appetite and blood sugar. The shift here is not the biology but the form: the same weight-loss category that built demand with weekly injections is now moving into tablets. (fda.gov) (lilly.com) (fda.gov) Foundayo’s pitch is convenience. Lilly says the once-daily pill can be taken any time of day without food or water restrictions, while Amazon Pharmacy said on April 8 that it would offer same-day delivery in nearly 3,000 cities and towns, expanding to nearly 4,500 by the end of 2026. (lilly.com) (businesswire.com) Amazon said insured patients may see pricing as low as $25 a month, or about $1 a day, while cash-pay customers would pay $149 a month after automatic manufacturer coupons. The company also said remote customers would get one-, two- or three-day delivery where other mail-order service can take five to 10 days. (businesswire.com) Clinical data are part of the sales pitch too. Lilly said adults taking the highest Foundayo dose in the ATTAIN-1 trial lost an average of 27 pounds, and the American Journal of Managed Care reported placebo-adjusted weight loss of roughly 9 to 11 percentage points at 72 weeks across the program. (prnewswire.com) (ajmc.com) Both products carry familiar safety baggage from the glucagon-like peptide-1 class. Wegovy’s label warns about thyroid C-cell tumors seen in rodents and says the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. (fda.gov) The immediate contest now looks less like a lab race than a fulfillment race. With two approved obesity pills on the market and Amazon turning delivery speed and checkout pricing into part of the offer, the next pressure point is whether patients can actually get them. (businesswire.com) (lilly.com)